Open Access Articles- Top Results for Pimavanserin


Systematic (IUPAC) name
Clinical data
Pharmacokinetic data
Protein binding 94-97%[1]
Half-life 54-56 hours[1]
706779-91-1 7pxY
706782-28-7 (tartrate)
PubChem CID 10071196
ChemSpider 8246736 7pxN
Chemical data
Formula C25H34FN3O2
427.553 g/mol
 14pxN (what is this?)  (verify)

Pimavanserin (ACP-103), marketed under the trade name Nuplazid, is a drug developed by Acadia Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors.[1] As of September 3 2009, pimavanserin has not met expectations for Phase III clinical trials for the treatment of Parkinson's disease psychosis,[2] and is in Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication.[3] It is expected to improve the effectiveness and side effect profile of antipsychotics.[4][5][6] The results of a clinical trial examining the efficacy, tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012 and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improve the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms.[7]

On September 2, 2014, the United States Food and Drug administration granted Breakthrough Therapy status to Acadia's New Drug Application for pimavanserin.[8]


  1. ^ a b c Friedman, JH (October 2013). "Pimavanserin for the treatment of Parkinson’s disease psychosis". Expert Opinion on Pharmacotherapy 14 (14): 1969–1975. PMID 24016069. doi:10.1517/14656566.2013.819345. 
  2. ^ ACADIA Pharmaceuticals. "Treating Parkinson's Disease - Clinical Trial Pimavanserin - ACADIA". Retrieved 2009-04-11. [dead link]
  3. ^ "ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial" (Press release). ACADIA Pharmaceuticals. 2007-03-19. Retrieved 2009-04-11. 
  4. ^ Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT et al. (Aug 2007). "ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models". The Journal of Pharmacology and Experimental Therapeutics 322 (2): 862–70. PMID 17519387. doi:10.1124/jpet.107.121715. 
  5. ^ Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM et al. (Oct 2008). "A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model". Pharmacology, Biochemistry, and Behavior 90 (4): 540–4. PMC 2806670. PMID 18534670. doi:10.1016/j.pbb.2008.04.010. 
  6. ^ Abbas A, Roth BL (Dec 2008). "Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders". Expert Opinion on Pharmacotherapy 9 (18): 3251–9. PMID 19040345. doi:10.1517/14656560802532707. 
  7. ^ Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P et al. (Nov 2012). "Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day". Schizophrenia Research 141 (2-3): 144–152. PMID 22954754. doi:10.1016/j.schres.2012.07.029. 
  8. ^ "ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis". Press Releases. Acadia. 2014-09-02. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.